| Cat. No. | Product Name | Action | Description |
|---|
3700 | Imiquimod | TLR7 agonist | TRL7 activation induces release of proinflammatory cytokines and activation of NF-κB signaling. Imiquimod activates antigen presenting cells and antitumor cellular immune response. |
5698 | 1-Methyl-D-tryptophan | IDO inhibitor | IDO activity in tumors inhibits proliferation and induces apoptosis of T-cells. Inhibition with 1-Methyl-D-tryptophan enhances the antitumor immune response of T-cells in vitro. |
5794 | LM 10 | TDO inhibitor | TDO is expressed in tumors and prevents immune rejection of tumor cells. Inhibition with LM 10 restores ability of mice to reject TDO expressing tumors. |
5872 | AZ 10397767 | CXCR2 antagonist | CXCR2 ligands recruit neutrophils to tumors. Antagonism with AZ 10397767 reduces recruitment both in vitro and in vivo and is associated with slower growing tumors. |
5945 | 2’,3’-cGAMP sodium salt | STING agonist | 2’,3’-cGAMP binds to stimulator of interferon genes (STING) to activate the innate immune response. Causes repolarization of TAMs to antitumor phenotype. |
6007 | INCB 024360-analog | IDO inhibitor | Inhibition of IDO with INCB 024360-analog enhances antitumor immune response and inhibits tumor growth in vivo. |
6083 | PSB 12379 | Ecto-5'-nucleotidase (CD73) inhibitor | CD73 catalyzes hydrolysis of extracellular AMP to adenosine, which causes local immunosuppression via adenosine receptors. Inhibition with PSB 12379 causes immune response in tumor microenvironment. |
